Phase II Failure Casts Shadow Over Biota Flu Drug
This article was originally published in PharmAsia News
Executive Summary
Biota Pharmaceuticals has said its laninamivir influenza A and B drug failed a Phase II international clinical trial comparing it with placebo, and that it has no plans to develop it independently for the indication.